Konica CR mammography system magnifies edge effects
A new phase-contrast CR mammography system that magnifies edge effects from x-ray refraction is sharpening contrast at the edges of the breast. The system, unveiled today at the RSNA meeting, also enhances the visualization of microcalcifications and fibrils within the breast, according to representatives from Konica Minolta.
A new phase-contrast CR mammography system that magnifies edge effects from x-ray refraction is sharpening contrast at the edges of the breast. The system, unveiled today at the RSNA meeting, also enhances the visualization of microcalcifications and fibrils within the breast, according to representatives from Konica Minolta.
The Regius PureView Mammography System combines phase-contrast mammography technology with computed radiography to produce digital mammography images with the same resolution as screen-film images.
The device uses a molybdenum x-ray tube with a 100-micron focal spot. The system also selects the optimal combination of x-ray focal spot size, the distance between the x-ray source and the breast, the distance between the x-ray source and the detector, and the sampling pitch of the CR reader, which scans images at 43.75 micrometers to produce a resolution of 20 line pair per millimeter.
The CR mammography system, which was introduced 10 months ago in Japan, is being tested in clinical trials prior to submission to the FDA for approval.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
